SAN DIEGO, April 16, 2025 /PRNewswire/ -- Neurelis, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved VALTOCO® (diazepam nasal spray) for short-term treatment of ...
In this younger patient population, diazepam nasal spray was readily absorbed and demonstrated a consistent PK profile with that of older children and adults aged 6 to 59 years. The Food and Drug ...
Valtoco (diazepam) is a prescription drug that’s used to treat seizure clusters in adults and certain children. Valtoco comes as a nasal spray. Valtoco contains the active ingredient diazepam. It ...
The FDA has approved Valtoco (diazepam nasal spray; Neurelis) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual ...
Analysis of 12-month, Phase 3 study shows 2-fold increase in time between VALTOCO treated seizure clusters, or SEIzure interVAL (SEIVAL) SAN DIEGO, Oct. 12, 2022 /PRNewswire/ -- Neurelis, Inc., a ...
VALTOCO maintains orphan drug exclusivity for VALTOCO to treat episodes of frequent seizures SAN DIEGO, April 16, 2025 /PRNewswire/ -- Neurelis, Inc., today announced that the U.S. Food and Drug ...
Valtoco (diazepam nasal spray) is a prescription medicine for quick and effective treatment of seizure clusters, also known as acute repetitive seizures, in people with epilepsy. Seizure clusters are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results